Biomarkers associated with coronary high-risk plaques.
Akihiro NakajimaPeter LibbySatoru MitomoHaruhito YukiMakoto ArakiLena Marie SeegersIris McNultyHang LeeMidori IshibashiKazuna KobayashiJouke DijkstraToru OuchiHirokazu OnishiHiroto YabushitaSatoshi MatsuokaHiroyoshi KawamotoYusuke WatanabeKentaro TanakaShengpu ChouTomohiko SatoToru NaganumaMasaaki OkutsuSatoko TaharaNaoyuki KuritaShotaro NakamuraDavid J KuterSunao NakamuraIk-Kyung JangPublished in: Journal of thrombosis and thrombolysis (2022)
Vascular inflammation, lipid metabolism, and thrombogenicity play a key role not only in atherogenesis but also in the development of acute coronary syndromes. Biomarkers associated with coronary high-risk plaques defined according to intravascular imaging have not been systematically studied. A total of 69 patients with coronary artery disease who underwent both optical coherence tomography and intravascular ultrasound imaging, and who provided blood specimens were included. Comprehensive biomarkers for inflammation, lipid, and coagulation were analyzed. Composite models sought biomarker patterns associated with thin-cap fibroatheroma (TCFA) and "high-risk plaques" (TCFA and large plaque burden). Two different composite models were developed for TCFA, based on the finding that high sensitivity C-reactive protein (hsCRP), plasminogen activator inhibitor-1, fibrinogen, IL-6, homocysteine and amyloid A levels were elevated, and high-density lipoprotein cholesterol (HDL) and bile acid levels were decreased in these patients. Both composite models were highly accurate for detecting patients with TCFA (area under curve [AUC]: 0.883 in model-A and 0.875 in model-B, both p < 0.001). In addition, creatinine, hsCRP, fibrinogen, tumor necrosis factor-α, IL-6, homocysteine, amyloid A, HDL, prothrombin, and bile acid were useful for detecting patients with "high-risk plaques". Two composite models were highly accurate for detection of patients with "high-risk plaques" (AUC: 0.925 in model-A and 0.947 in model-B, both p < 0.001). Biomarkers useful for detection of patients with high-risk coronary plaques defined according to intravascular imaging have been identified. These biomarkers may be useful to risk stratify patients and to develop targeted therapy.Clinical Trial Registration https://www.umin.ac.jp/ctr/ , UMIN000041692. Biomarkers and high-risk plaques hsCRP, PAI-1, fibrinogen, IL-6, homocysteine, amyloid A, HDL, and bile acid were useful for detecting patients with TCFA. hsCRP, fibrinogen, IL-6, homocysteine, amyloid A, creatinine, TNFα, HDL, prothrombin, and bile acid were useful for detecting patients with "high-risk plaques" (plaque which has both TCFA and large plaque burden). White arrowhead denotes TCFA. Red and green dashed lines denote lumen area and external elastic membrane area, respectively.
Keyphrases
- coronary artery
- coronary artery disease
- clinical trial
- high resolution
- end stage renal disease
- newly diagnosed
- oxidative stress
- optical coherence tomography
- rheumatoid arthritis
- prognostic factors
- randomized controlled trial
- metabolic syndrome
- fatty acid
- risk factors
- left ventricular
- aortic stenosis
- atrial fibrillation
- fluorescence imaging
- solid state